YU.V. KARAKULOVA, N.E. SEKSYAEV, D.YU. SOSNIN

 Perm State Medical University named after Academician E. A. Wagner, Perm

 Contact details:

Karakulova Yu.V. — MD, Professor, Head of the Department of Neurology and Medical Genetics

Address: 26 Petropavlovskaya St., Perm, Russian Federation, 614990, tel.: +7912-884-40-07, e-mail: julia.karakulova@mail.ru

One of the main causes of cognitive dysfunction in a late stage of HIV infection is HIV-associated encephalopathy. The direct neurotropic impact of HIV creates the pathogenic basis for this clinical syndrome.

The purpose — to evaluate the cognitive status and neuron-specific enolase (NSE) level in cerebrospinal fluid (CSF) in HIV-encephalopathy patients.

Material and methods. 35 patients were included in the study. They were divided into two groups: 20 patients (9 females and 11 males) with cognitive dysfunction and confirmed diagnosis of HIV/AIDS and 15 patients (6 females and 9 males) were in comparison group. The cognitive status was investigated by mini-mental state examination (MMSE), international HIV-dementia scale (IHDS) and frontal assessment battery (FAB). CSF level of NSE were investigated by ELISA test.

Results. Correlation between cognitive dysfunction severity and NSE level in CSF was determined in HIV-encephalopathy patients.

Conclusion. NSE level changing in CSF is an objective indicator of clinical severity of HIV-encephalopathy and neurotropic impact of HIV.

Key words: HIV, neuroAIDS, HIV-associated encephalopathy, cognitive dysfunction, neuron-specific enolase, cerebrospinal fluid.

REFERENCES

1. Clifford D.B., Ances B.M. HIV-associated neurocognitive disorder. Lancet Infect Dis, 2013, vol. 13 (11), pp. 976–986. DOI:10.1016/S1473-3099(13)70269-X
2. Antinori A., Arendt G., Becker J.T. et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology, 2007, vol. 69 (18), pp. 1789–1799. DOI: 10.1212/01.WNL.0000287431.88658.8b
3. Chilunda V., Calderon T.M., Martinez-Aguado P., Berman J.W. The impact of substance abuse on HIV-mediated neuropathogenesis in the current ART era. Brain Res, 2019, p. 1724:146426. DOI: 10.1016/j.brainres.2019.146426
4. Smirnov A.A., Gustov A.V., Kopishinskaya S.V., Antonova V.A. Pre-dementia states and dementia in young people. Nevrologiya, neyropsikhiatriya, psikhosomatika, 2014, vol. 6, no. 2, pp. 41–43 (in Russ.).
5. Ellis R.J., Badiee J., Vaida F. et al. CD4 nadir is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS, 2011, vol. 25 (14), pp. 1747–1751. DOI: 10.1097/QAD.0b013e32834a40cd
6. Brew B.J., Barnes S.L. The impact of HIV central nervous system persistence on pathogenesis. AIDS, 2019, vol. 33 (2), pp. 113–S121. DOI: 10.1097/QAD.0000000000002251
7. Spudich S., González-Scarano F. HIV-1-related central nervous system disease: current issues in pathogenesis, diagnosis, and treatment. Cold Spring Harb Perspect Med, 2012, vol. 2 (6), p. a007120. DOI: 10.1101/cshperspect.a007120
8. Saylor D., Dickens A.M., Sacktor N. et al. HIV-associated neurocognitive disorder-pathogenesis and prospects for treatment. Nat. Rev. Neurol, 2016, vol. 12 (4), pp. 234–248. DOI: 10.1038/nrneurol.2016.27
9. Parfenov V.A., Kulesh A.A. Cerebrovascular disease with cognitive impairment. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova, 2021, vol. 121 (9), pp. 121–130 (in Russ.). DOI: 10.17116/jnevro2021121091121
10. Sacktor N., Skolasky R.L., Seaberg E. et al. Prevalence of HIV-associated neurocognitive disorders in the Multicenter AIDS Cohort Study. Neurology, 2016, vol. 86 (4), pp. 334–340. DOI: 10.1212/WNL.0000000000002277
11. Clifford D.B., Fagan A.M., Holtzman D.M. et al. CSF biomarkers of Alzheimer disease in HIV-associated neurologic disease. Neurology, 2009, vol. 73 (23), pp. 1982–1987. DOI: 10.1212/WNL.0b013e3181c5b445
12. Jessen Krut J., Mellberg T., Price R.W. et al. Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS One, 2014, vol. 9 (2), p. e88591. DOI: 10.1371/journal.pone.0088591
13. Agoston D.V., Shutes-David A., Peskind E.R. Bio fluid biomarker so traumatic brain injury. Brain Inj., 2017, vol. 31, no. 9, pp. 1195-1203. doi:10.1080/02699052.2017.1357836
14. Haque A., Ray S.K., Cox A., Banik N.L. Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. Metab. Brain. Dis, 2016, vol. 31 (3), pp. 487–495. DOI: 10.1007/s11011-016-9801-6
15. Schmidt F.M., Mergl R., Stach B. et al. Elevated levels of cerebrospinal fluid neuron-specific enolase (NSE) in Alzheimer’s disease. Neurosci. Lett, 2014, vol. 570, pp. 81–85. DOI: 10.1016/j.neulet.2014.04.007
16. Isgrò M.A., Bottoni P., Scatena R. Neuron-Specific Enolase as a Biomarker: Biochemical and Clinical Aspects. Adv. Exp. Med. Biol, 2015, vol. 867, pp. 125–143. DOI: 10.1007/978-94-017-7215-0_9
17. Sidtis J.J., Price R.W. Early HIV-1 infection and the AIDS dementia complex. Neurology, 1990, vol. 40 (2), pp. 323–326. DOI: 10.1212/wnl.40.2.323
18. Masliah E., Heaton R.K., Marcotte T.D. et al. Dendritic injury is a pathological substrate for human immunodeficiency virus-related cognitive disorders HNRC Group. The HIV Neurobehavioral Research Center. Ann. Neurol, 1997, vol. 42 (6), pp. 963–972. DOI: 10.1002/ana.410420618
19. Ellis R., Langford D., Masliah E. HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat. Rev. Neurosci, 2007, vol. 8 (1), pp. 33–44. DOI: 10.1038/nrn2040
20. Karakulova Yu.V, Seksyaev N.E., Sosnin D.Yu. Sposob diagnostiki kognitivnykh narusheniy u patsientov s VICh-assotsiirovannoy entsefalopatiey v stadii SPID [A method for diagnosing cognitive impairment in patients with HIV-associated encephalopathy in the AIDS stage]. Patent RF na izobretenie no. 2785490 C1/08.12.22.